[go: up one dir, main page]

CY1113395T1 - Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη - Google Patents

Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη

Info

Publication number
CY1113395T1
CY1113395T1 CY20121101126T CY121101126T CY1113395T1 CY 1113395 T1 CY1113395 T1 CY 1113395T1 CY 20121101126 T CY20121101126 T CY 20121101126T CY 121101126 T CY121101126 T CY 121101126T CY 1113395 T1 CY1113395 T1 CY 1113395T1
Authority
CY
Cyprus
Prior art keywords
sulfamidi
pharmaceutical composition
composition containing
stable pharmaceutical
containing pyrimidine
Prior art date
Application number
CY20121101126T
Other languages
English (en)
Inventor
Charles Tokunbo Adesuyi
Lovelace Holman
Olivier Lambert
Bruce Hamilton Lithgow
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113395(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY1113395T1 publication Critical patent/CY1113395T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται στις σταθερές φαρμακευτικές συνθέσεις που περιέχουν την ένωση του κάτωθι χημικού τύπου, ή τα φαρμακευτικά αποδεκτά άλατα, τα επιδιαλυτωμένα χημικά σωματίδια, τα ένυδρα άλατα ή τις μορφολογικές μορφές αυτών.
CY20121101126T 2005-09-12 2012-11-21 Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη CY1113395T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005009775 2005-09-12
EP06809280A EP1928409B1 (en) 2005-09-12 2006-09-11 Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Publications (1)

Publication Number Publication Date
CY1113395T1 true CY1113395T1 (el) 2016-06-22

Family

ID=37865339

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101126T CY1113395T1 (el) 2005-09-12 2012-11-21 Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη

Country Status (23)

Country Link
US (6) US20080233188A1 (el)
EP (2) EP2292209A3 (el)
JP (2) JP4955685B2 (el)
KR (1) KR101313395B1 (el)
CN (1) CN101262847B (el)
AU (1) AU2006290309B2 (el)
BR (1) BRPI0615898B8 (el)
CA (1) CA2621273C (el)
CY (1) CY1113395T1 (el)
DK (1) DK1928409T3 (el)
ES (1) ES2393117T3 (el)
HR (1) HRP20120957T1 (el)
IL (1) IL190072A (el)
MY (1) MY151003A (el)
NO (1) NO341325B1 (el)
NZ (1) NZ567188A (el)
PL (1) PL1928409T3 (el)
PT (1) PT1928409E (el)
RU (1) RU2424805C2 (el)
SI (1) SI1928409T1 (el)
TW (1) TWI323661B (el)
WO (1) WO2007031933A2 (el)
ZA (1) ZA200802947B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567188A (en) 2005-09-12 2011-04-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
RU2494736C2 (ru) 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
SI3300729T1 (sl) * 2008-08-13 2020-02-28 Actelion Pharmaceuticals Ltd. Terapevtski sestavki, ki vsebujejo macitentan
TWI483938B (zh) * 2009-08-10 2015-05-11 Univ Texas 以內皮素受體抑制劑處理星狀腫瘤細胞
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
IT1403248B1 (it) * 2010-11-12 2013-10-17 Scharper Therapeutics Srl Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
DK3007695T3 (da) 2013-06-13 2024-03-18 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
WO2014198178A1 (zh) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
EP3169669A1 (en) * 2014-07-15 2017-05-24 OLON S.p.A. Amorphous form and new crystalline forms of macitentan
SG11201700147SA (en) 2014-07-25 2017-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CN105388244B (zh) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦有关物质的高效液相色谱分析方法
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
MX2021007455A (es) 2018-12-21 2021-08-05 Actelion Pharmaceuticals Ltd Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar.
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
PT3974421T (pt) 2019-05-22 2024-10-03 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristalina de composto de pirimidina sulfonamida e método de preparação da mesma
EP3993777B1 (en) * 2019-07-05 2024-06-12 Tecnimede, Sociedade Técnico-Medicinal, SA Compressed macitentan compositions, methods and uses thereof
CN114728002A (zh) 2019-11-29 2022-07-08 埃科特莱茵药品有限公司 治疗肺动脉高血压的方法
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
WO2022258796A1 (en) * 2021-06-11 2022-12-15 Actelion Pharmaceuticals Ltd Dispersible tablet for oral administration
JP2024530727A (ja) 2021-08-25 2024-08-23 ビーエーエスエフ ソシエタス・ヨーロピア 直接打錠補助組成物
WO2023038600A1 (en) * 2021-09-07 2023-03-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation comprising macitentan
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6083955A (en) 1995-12-20 2000-07-04 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
JPH103525A (ja) 1996-06-14 1998-01-06 Dainippon Printing Co Ltd Ｉｃカード、命令コード格納方法及び命令コード実行方法
CO5021171A1 (es) 1997-12-08 2001-03-27 Smithkline Beechman Corp Sal de monoargininilo del acido(e)-3-(1-n-butil-5-(2-(2- carboxifenil)metoxi-4-clorofenil)-1h-pirazol-4-il)-2- ((5-metoxi-2,3-dihidrobenzofuran-5-il)metil)-prop-2-enoico
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20040062803A1 (en) * 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
EE200200363A (et) * 1999-12-31 2003-08-15 Texas Biotechnology Corporation Sulfoonamiidid ja nende derivaadid, mis moduleerivad endoteliini aktiivsust
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
HRP20030027A2 (en) 2000-06-28 2004-02-29 Teva Pharma Carvedilol
EP1364643A4 (en) 2000-12-01 2009-07-15 Kyowa Hakko Kogyo Kk COMPOSITION WITH IMPROVED SOLUBILITY OR ORAL ABSORBIBILITY
CA2430951A1 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
CN100432070C (zh) * 2000-12-18 2008-11-12 埃科特莱茵药品有限公司 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
JP3930290B2 (ja) 2001-09-12 2007-06-13 富士フイルム株式会社 熱現像感光材料及びそれを用いた熱現像方法
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
CA2472585A1 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Drug mixture with enhanced dissolution rate
CN1652782A (zh) 2002-02-11 2005-08-10 美国辉瑞有限公司 用作pde4抑制剂的烟酰胺衍生物
CA2476587C (en) * 2002-02-26 2010-05-04 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
EP1591120A4 (en) 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
MXPA05009098A (es) 2003-02-25 2005-11-17 Lilly Co Eli Clorhidrato de 1- (4-(2 -piperidiniletoxifenoxi) -2-(4-metansulfonilfenil) -6-hidroxinaftaleno cristalino no solvatado.
AU2004298983A1 (en) 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
NZ567188A (en) 2005-09-12 2011-04-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
RU2494736C2 (ru) 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
SI3300729T1 (sl) 2008-08-13 2020-02-28 Actelion Pharmaceuticals Ltd. Terapevtski sestavki, ki vsebujejo macitentan
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme

Also Published As

Publication number Publication date
DK1928409T3 (da) 2012-11-05
HK1121950A1 (en) 2009-05-08
US20160136163A1 (en) 2016-05-19
PT1928409E (pt) 2012-11-27
CA2621273A1 (en) 2007-03-22
TW200803860A (en) 2008-01-16
US20080233188A1 (en) 2008-09-25
US9265762B2 (en) 2016-02-23
SI1928409T1 (sl) 2012-12-31
EP1928409B1 (en) 2012-09-12
US20180263980A1 (en) 2018-09-20
IL190072A0 (en) 2008-08-07
KR101313395B1 (ko) 2013-10-02
US11648249B2 (en) 2023-05-16
MY151003A (en) 2014-03-31
TWI323661B (en) 2010-04-21
NZ567188A (en) 2011-04-29
BRPI0615898B1 (pt) 2020-02-18
RU2424805C2 (ru) 2011-07-27
JP2009235073A (ja) 2009-10-15
HRP20120957T1 (hr) 2012-12-31
BRPI0615898B8 (pt) 2021-05-25
US10117870B2 (en) 2018-11-06
PL1928409T3 (pl) 2013-02-28
NO20081724L (no) 2008-04-09
CN101262847A (zh) 2008-09-10
US8367685B2 (en) 2013-02-05
US20210186966A1 (en) 2021-06-24
WO2007031933A2 (en) 2007-03-22
NO341325B1 (no) 2017-10-16
BRPI0615898A2 (pt) 2011-05-31
KR20080055897A (ko) 2008-06-19
WO2007031933A3 (en) 2007-10-18
EP2292209A2 (en) 2011-03-09
JP2009519893A (ja) 2009-05-21
CN101262847B (zh) 2010-11-24
US20100004274A1 (en) 2010-01-07
EP1928409A2 (en) 2008-06-11
EP2292209A3 (en) 2011-05-04
IL190072A (en) 2013-08-29
ES2393117T3 (es) 2012-12-18
US10946015B2 (en) 2021-03-16
US20130190336A1 (en) 2013-07-25
JP5054061B2 (ja) 2012-10-24
AU2006290309A1 (en) 2007-03-22
RU2008113869A (ru) 2009-10-20
CA2621273C (en) 2014-07-29
JP4955685B2 (ja) 2012-06-20
AU2006290309B2 (en) 2012-04-05
ZA200802947B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
EA200970156A1 (ru) Пиридизиноновые производные
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
UA94833C2 (en) Substituted bicyclolactams
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA200702497A1 (ru) Замещенные арилпиразолы для применения против паразитов
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
SE0400284D0 (sv) Novel compounds
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
TW200612936A (en) Indole derivatives
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
MX2009008028A (es) Agentes antiparasitarios.
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201290229A1 (ru) Производные спиролактама и их применение
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA200901030A1 (ru) Антагонист хроменового рецептора s1p1